Health
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger – Business Wire
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the

CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.
…
-
General8 hours ago
Campers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Business16 hours ago
Bell Potter names the best ASX shares to buy in October
-
Noosa News15 hours ago
Perth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
General13 hours ago
Australia welcomes Gaza peace progress, hostage release